Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
News|Articles|February 23, 2017
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-03-01-2017
- Volume 12
- Issue 3
Kemwell Announces Successful FDA Inspection at Bangalore Facility
Author(s)Pharmaceutical Technology Editors
The company announced that no Form 483 was observed at the company’s facility in Bangalore, India.
Advertisement
On Feb. 20, 2017, Kemwell Biopharma announced that its oral solids manufacturing facility in Bangalore, India successfully completed an FDA inspection. The inspection confirmed that the site is compliant with principles of current good manufacturing practices and no Form 483 observations were issued. In a statement, the company said the audit was triggered by an abbreviated new drug application filed for a customer. This facility is part of Kemwell’s pharmaceutical business for which Kemwell has signed a purchase agreement with Recipharm.
Source: Kemwell
Articles in this issue
over 9 years ago
Viewpoint: No Clear Path for Pharma or Outsourcingover 9 years ago
Standards Set Excipient GMPs, But Collaboration is Neededover 9 years ago
Monitoring Supply Chain Risk on a Limited Budgetover 9 years ago
Evaluating E&L Studies for Single-Use Systemsover 9 years ago
PfizerCentreOne Expands Fill/Finish Services in Michiganover 9 years ago
Metrohm USA Announces Winner of Young Chemist Awardover 9 years ago
Novasep Opens New Bioconjugation Unit in Franceover 9 years ago
Recipharm Completes Kemwell AcquisitionAdvertisement
Related to this article
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
Univar Solutions scientists developed a lidocaine cream built on starch, sorbitol, coconut oil, and beeswax that matched a commercial benchmark on viscosity, assay, and hydration.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Nitrosamine Problems and Industry Solutions: PharmTech Explained
2
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
3
AAPS PharmSci 360 2026: E&L Standards Harmonization
4
Formulation and Evaluation of a Sustainable Analgesic Cream Utilizing Renewable Bio-Based Ingredients and Green Chemistry Design Principles
5